What is Rallybio Corporation's earnings per share (EPS)?

Rallybio Corporation (RLYB) reported diluted earnings per share of -$1.59 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Rallybio Corporation (RLYB) Financials

RLYB

Trailing 12 months to June 30, 2026

Revenue $646K YoY not available

Net Income $45.6M YoY not available

EPS (Diluted) -$1.59 FY2025 annual

Operating Cash Flow $26.7M +163.6% YoY

Market Cap $90.3M as of Oct 8, 2026

Price / Sales 140x on $646K revenue, trailing 12 months to June 30, 2026

Price / Earnings 2.0x on $45.6M net income, trailing 12 months to June 30, 2026

Price / Book 1.0x on $94.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 26, 2026 Currency USD FYE December

Newest figures come from the S-4/A for Q2 FY2026, filed Aug 26, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RLYB SEC filings page.

Rallybio Corporation (RLYB) reported $646K in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RLYB FY2025 2026-10-04

Rallybio remains development-stage: lower research spending is narrowing losses, while investing inflows—not revenue—support its cash position.

Cash conversion remains weaker than accounting results: FY2025 reported a net loss of $9.0M but operating cash outflow of $29.8M, showing that the reported loss understated the period’s cash requirement. At the same time, investing cash inflows of $47.3M exceeded that operating outflow, so the cash pattern depended on investing activity rather than internally generated operations.

Expense reduction, not commercial scale, drove the improvement. Research and development fell to $19.6M in FY2025 from $41.5M in FY2024, helping operating loss narrow to $33.1M; revenue of only $858K remains small relative to that cost base.

The balance sheet is lightly burdened by liabilities: FY2025 liabilities were $4.3M against $62.3M of assets, while the current ratio was 14.5x. Reported liquidity equaled 22 months of the latest annual operating outflow, but the company still relied on investing inflows because operating cash flow remained negative.

Financial Health Signals

Financial health score not available

Rallybio Corporation does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

5.15

Rallybio Corporation scores 5.15, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($90.3M) relative to total liabilities ($4.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/7

Rallybio Corporation passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Rallybio Corporation reported a net loss of $9.0M while operations used $29.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

QoQ-100.0%

Rallybio Corporation generated $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

EBITDA

-$5.7M

YoY+43.7%

QoQ+35.3%

Rallybio Corporation's EBITDA was -$5.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 43.7% from the same quarter a year earlier. Against the prior quarter it is up 35.3%.

Net Income

$43.7M

YoY+550.0%

QoQ+627.5%

Rallybio Corporation reported $43.7M in net income in Q2 2026. This represents an increase of 550.0% from the same quarter a year earlier. Against the prior quarter it is up 627.5%.

EPS (Diluted)

$7.53

QoQ+615.8%

Rallybio Corporation earned $7.53 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 615.8%.

Cash & Balance Sheet

Cash & Debt

$92.8M

YoY+883.0%

QoQ+124.8%

5Y CAGR-3.8%

Rallybio Corporation held $92.8M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ+0.2%

5Y CAGR-30.2%

Rallybio Corporation had 5M shares outstanding in Q2 2026. Against the prior quarter it is up 0.2%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

46.2%

YoY+67.3pp

QoQ+62.7pp

Rallybio Corporation's ROE was 46.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 67.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 62.7 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$758K

YoY-87.5%

QoQ-73.6%

Rallybio Corporation invested $758K in research and development in Q2 2026. This represents a decrease of 87.5% from the same quarter a year earlier. Against the prior quarter it is down 73.6%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

RLYB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RLYB quarterly income statement

Metric	TTM	FY25S-4/A	FY24S-4/A	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	$646K	$858K+34.9%	$636K	N/A	N/A	N/A	N/A
R&D Expenses	$11.4M	$19.6M-52.8%	$41.5M-22.5%	$53.5M+31.6%	$40.7M+51.2%	$26.9M+52.6%	$17.6M
SG&A Expenses	$16.9M	$14.3M-27.0%	$19.6M-22.7%	$25.4M-6.6%	$27.2M+45.1%	$18.7M+144.2%	$7.7M
Operating Income	-$27.7M	-$33.1M+45.3%	-$60.5M+23.4%	-$78.9M-16.3%	-$67.9M-48.7%	-$45.6M-80.4%	-$25.3M
EBITDA	N/A	-$33.0M+45.4%	-$60.4M+23.4%	-$78.8M-16.3%	-$67.7M-48.7%	-$45.5M-80.4%	-$25.2M
Interest Expense	N/A	N/A	N/A	N/A	$0-100.0%	$10K-79.6%	$49K
Income Tax	N/A	$0	$0	$0	$0	$0+100.0%	-$15K
Net Income	$45.6M	-$9.0M+84.5%	-$57.8M+22.5%	-$74.6M-11.9%	-$66.7M-41.8%	-$47.0M-77.8%	-$26.4M
EPS (Basic)	N/A	-$1.59+85.0%	-$10.61-476.6%	-$1.84+12.0%	-$2.09-13.6%	-$1.84	N/A
EPS (Diluted)	—	-$1.59	-$10.61	-$1.84+12.0%	-$2.09-13.6%	-$1.84	N/A
Diluted Shares (Avg)	N/A	6M	5M	40M+27.1%	32M+24.7%	26M	N/A

Metric	Q2'26S-4/A	Q1'26S-4	Q4'25S-4/A	Q3'2510-Q	Q2'25S-4/A	Q1'25S-4	Q4'24S-4/A	Q3'2410-Q
Revenue	$0-100.0%	$212K0.0%	$222K	$212K-29.1%	$212K-29.1%	$212K	N/A	$299K
R&D Expenses	$758K-87.5%	$2.9M-49.9%	$3.7M	$4.1M-49.7%	$6.1M-53.1%	$5.7M-55.7%	N/A	$8.2M-38.0%
SG&A Expenses	$4.9M+16.7%	$6.1M+46.1%	$3.0M	$3.0M-27.4%	$4.2M-4.4%	$4.2M-39.3%	N/A	$4.1M-32.1%
Operating Income	-$5.7M+43.8%	-$8.7M+9.7%	-$6.4M	-$6.9M+42.6%	-$10.1M+41.0%	-$9.7M+51.1%	N/A	-$12.1M+37.7%
EBITDA	-$5.7M+43.7%	-$8.7M+9.5%	-$6.4M	-$6.9M+42.7%	-$10.0M+41.0%	-$9.6M+51.2%	N/A	-$12.0M+37.7%
Income Tax	$1.3M	N/A	N/A	N/A	$0	N/A	N/A	N/A
Net Income	$43.7M+550.0%	-$8.3M+12.3%	-$5.9M	$16.0M+239.7%	-$9.7M+40.2%	-$9.4M+50.4%	N/A	-$11.5M+37.6%
EPS (Basic)	$7.66+542.8%	-$1.46+13.6%	-$1.52-508.0%	$0.36+238.5%	-$1.73-367.6%	-$1.69-259.6%	-$0.25+49.0%	-$0.26+42.2%
EPS (Diluted)	$7.53	-$1.46	-$1.52	$0.36+238.5%	-$0.22+40.5%	-$1.69	-$0.25+49.0%	-$0.26+42.2%
Diluted Shares (Avg)	6M	6M	N/A	45M+1.0%	45M+1.6%	6M	N/A	45M+10.0%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

RLYB Balance Sheet

RLYB quarterly balance sheet

Metric	FY25S-4/A	FY24S-4/A	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$62.3M-8.6%	$68.1M-41.1%	$115.6M-35.9%	$180.4M-1.0%	$182.2M+28.4%	$141.9M
Current Assets	$61.3M-9.7%	$67.8M-40.9%	$114.8M-36.0%	$179.5M-0.8%	$180.9M+28.0%	$141.3M
Cash & Equivalents	$31.4M+125.7%	$13.9M-43.2%	$24.5M-57.0%	$57.0M-67.5%	$175.3M+25.0%	$140.2M
Short-Term Investments	$23.4M-54.7%	$51.6M-39.6%	$85.4M-23.7%	$112.0M	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0
Total Liabilities	$4.3M-33.3%	$6.5M-31.6%	$9.4M-15.1%	$11.1M+68.9%	$6.6M+12.4%	$5.9M
Current Liabilities	$4.2M-32.3%	$6.2M-32.6%	$9.3M-13.8%	$10.7M+64.0%	$6.6M+12.1%	$5.8M
Non-Current Liabilities	$82K-61.3%	$212K+22.5%	$173K-53.7%	$374K+1068.8%	$32K+166.7%	$12K
Total Equity	$58.0M-6.0%	$61.7M-41.9%	$106.2M-37.3%	$169.3M-3.6%	$175.6M+29.1%	$136.0M
Retained Earnings	-$302.0M-3.1%	-$293.0M-24.6%	-$235.2M-46.4%	-$160.7M-70.9%	-$94.0M-100.0%	-$47.0M

Metric	Q2'26S-4/A	Q1'26S-4	Q4'25S-4/A	Q3'2510-Q	Q2'25S-4/A	Q1'25S-4	Q4'24S-4/A	Q3'2410-Q
Total Assets	$98.1M+92.3%	$54.5M-6.1%	$62.3M-8.6%	$67.7M-14.4%	$51.0M-44.8%	$58.0M-41.6%	$68.1M-41.1%	$79.0M-40.7%
Current Assets	$97.3M+93.5%	$53.5M-6.8%	$61.3M-9.7%	$66.6M-14.8%	$50.3M-45.0%	$57.4M-41.8%	$67.8M-40.9%	$78.2M-40.9%
Cash & Equivalents	$92.8M+883.0%	$41.3M+179.4%	$31.4M+125.7%	$32.1M+26.9%	$9.4M-43.3%	$14.8M-23.4%	$13.9M-43.2%	$25.3M+32.2%
Short-Term Investments	$0-100.0%	$5.5M-86.2%	$23.4M-54.7%	$27.2M-45.4%	$36.3M-49.5%	$39.7M-47.0%	$51.6M-39.6%	$49.8M-51.3%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$3.6M-29.2%	$4.2M+7.3%	$4.3M-33.3%	$4.6M-43.5%	$5.0M-59.4%	$3.9M-61.7%	$6.5M-31.6%	$8.2M-14.8%
Current Liabilities	$3.6M-29.2%	$4.1M+5.9%	$4.2M-32.3%	$4.5M-44.8%	$5.0M-58.6%	$3.9M-61.2%	$6.2M-32.6%	$8.2M-12.9%
Non-Current Liabilities	$0	$55K	$82K-61.3%	$108K	$0-100.0%	$0-100.0%	$212K+22.5%	$0-100.0%
Total Equity	$94.5M+105.6%	$50.3M-7.0%	$58.0M-6.0%	$63.0M-11.0%	$46.0M-42.6%	$54.1M-39.4%	$61.7M-41.9%	$70.8M-42.7%
Retained Earnings	-$266.6M+14.6%	-$310.3M-2.6%	-$302.0M-3.1%	-$296.1M-5.0%	-$312.2M-15.4%	-$302.5M-19.0%	-$293.0M-24.6%	-$282.0M-31.1%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

RLYB Cash Flow Statement

RLYB quarterly cash flow statement

Metric	TTM	FY25S-4/A	FY24S-4/A	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	$26.7M	-$29.8M+39.5%	-$49.3M+18.2%	-$60.3M-5.2%	-$57.3M-25.8%	-$45.5M-106.6%	-$22.0M
Depreciation & Amortization	N/A	$92K-29.8%	$131K-12.7%	$150K-10.2%	$167K+53.2%	$109K+75.8%	$62K
Stock-Based Compensation	N/A	$5.3M-33.5%	$8.0M-26.8%	$10.9M+15.0%	$9.5M+160.6%	$3.6M+417.8%	$704K
Capital Expenditures	N/A	N/A	$0-100.0%	$12K-77.8%	$54K-83.8%	$333K+143.1%	$137K
Free Cash Flow	N/A	N/A	-$49.3M+18.2%	-$60.3M-5.1%	-$57.3M-25.0%	-$45.9M-106.8%	-$22.2M
Investing Cash Flow	$56.6M	$47.3M+41.1%	$33.5M+21.1%	$27.7M+124.7%	-$112.2M-4708.0%	-$2.3M-12.6%	-$2.1M
Financing Cash Flow	$140K	$16K-99.7%	$5.2M+3535.7%	$143K-99.7%	$51.1M-38.4%	$83.0M-42.7%	$144.9M

Metric	Q2'26S-4/A	Q1'26S-4	Q4'25S-4/A	Q3'2510-Q	Q2'25S-4/A	Q1'25S-4	Q4'24S-4/A	Q3'2410-Q
Operating Cash Flow	$45.9M+648.0%	-$8.0M+21.8%	-$4.7M+52.6%	-$6.5M+51.6%	-$8.4M+19.6%	-$10.2M+34.0%	-$9.9M+15.3%	-$13.5M+17.8%
Depreciation & Amortization	$2K-92.3%	$3K-89.3%	$3K-90.0%	$35K+9.4%	$26K-23.5%	$28K-20.0%	$30K-16.7%	$32K-13.5%
Stock-Based Compensation	$424K-73.7%	$613K-67.4%	N/A	$1.0M-48.3%	$1.6M-15.7%	$1.9M-10.0%	N/A	$2.0M-23.0%
Investing Cash Flow	$5.5M+81.2%	$17.9M+61.5%	$3.9M+349.5%	$29.2M+31.6%	$3.0M+16.9%	$11.1M+8.0%	-$1.6M-109.3%	$22.2M+623.3%
Financing Cash Flow	$131K+1210.0%	$3K	$6K-66.7%	$0+100.0%	$10K-99.8%	$0	$18K-75.0%	-$11K

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

RLYB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RLYB quarterly financial ratios

Metric	FY25S-4/A	FY24S-4/A	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Margin	-3853.6%	-9512.0%	N/A	N/A	N/A	N/A
Net Margin	-1046.4%	-9084.1%	N/A	N/A	N/A	N/A
Return on Equity	-15.5%+78.2pp	-93.7%-23.5pp	-70.2%-30.9pp	-39.4%-12.6pp	-26.8%-7.3pp	-19.4%
Return on Assets	-14.4%+70.4pp	-84.8%-20.3pp	-64.5%-27.6pp	-36.9%-11.1pp	-25.8%-7.2pp	-18.6%
Current Ratio	14.50+3.6x	10.87-1.5x	12.39-4.3x	16.71-10.9x	27.61+3.4x	24.18
Debt-to-Equity	0.070.0x	0.100.0x	0.090.0x	0.070.0x	0.040.0x	0.04
Asset Turnover	0.010.0x	0.01	N/A	N/A	N/A	N/A
FCF Margin	N/A	-7748.7%	N/A	N/A	N/A	N/A

Metric	Q2'26S-4/A	Q1'26S-4	Q4'25S-4/A	Q3'2510-Q	Q2'25S-4/A	Q1'25S-4	Q4'24S-4/A	Q3'2410-Q
Operating Margin	N/A	-4119.3%	-2888.3%	-3266.5%	-4743.9%	-4561.3%	N/A	-4035.5%
Net Margin	N/A	-3904.7%	-2636.0%	7554.7%	-4576.9%	-4452.4%	N/A	-3834.8%
Return on Equity	46.2%+67.3pp	-16.5%+1.0pp	-10.1%	25.4%+41.6pp	-21.1%-0.8pp	-17.5%+3.9pp	N/A	-16.2%-1.3pp
Return on Assets	44.5%+63.5pp	-15.2%+1.1pp	-9.4%	23.7%+38.2pp	-19.0%-1.5pp	-16.3%+2.9pp	N/A	-14.5%-0.7pp
Current Ratio	27.26+17.3x	12.92-1.8x	14.50+3.6x	14.74+5.2x	9.98+2.5x	14.68+4.9x	10.87-1.5x	9.55-4.5x
Debt-to-Equity	0.04-0.1x	0.080.0x	0.070.0x	0.070.0x	0.110.0x	0.070.0x	0.100.0x	0.120.0x
Asset Turnover	0.000.0x	0.000.0x	0.00	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Rallybio Corporation RLYB	FY2025	$858K	-$9.0M	N/A	$90.3M	—
Boundless Bio, Inc. BOLD	FY2025	N/A	-$58.2M	N/A	$60.1M	—
Rein Therapeutics, Inc. RNTX	FY2025	$0	-$49.9M	N/A	$68.0M	—
Akari Therapeutics plc AKTX	FY2025	N/A	-$17.3M	N/A	$19.7M	—
SeaStar Medical Holding Corporation ICU	FY2025	$1.2M	-$12.2M	N/A	$19.6M	44/100
Lixte Biotechnology Holdings, Inc. LIXT	FY2025	N/A	-$6.1M	N/A	$125.4M	—

Where Rallybio Corporation Ranks

Frequently Asked Questions

What is Rallybio Corporation's annual revenue?

Rallybio Corporation (RLYB) reported $858K in total revenue for fiscal year 2025. This represents a 34.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Rallybio Corporation's revenue growing?

Rallybio Corporation (RLYB) revenue grew by 34.9% year-over-year, from $636K to $858K in fiscal year 2025.

Is Rallybio Corporation profitable?

No, Rallybio Corporation (RLYB) reported a net income of -$9.0M in fiscal year 2025.

What is Rallybio Corporation's EBITDA?

Rallybio Corporation (RLYB) had EBITDA of -$33.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Rallybio Corporation's return on equity (ROE)?

Rallybio Corporation (RLYB) has a return on equity of -15.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Rallybio Corporation's operating cash flow?

Rallybio Corporation (RLYB) recorded an outflow of $29.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Rallybio Corporation's total assets?

Rallybio Corporation (RLYB) had $62.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Rallybio Corporation spend on research and development?

Rallybio Corporation (RLYB) invested $19.6M in research and development during fiscal year 2025.

How many shares does Rallybio Corporation have outstanding?

Rallybio Corporation (RLYB) had 5M shares outstanding as of fiscal year 2025.

What is Rallybio Corporation's current ratio?

Rallybio Corporation (RLYB) had a current ratio of 14.50 as of fiscal year 2025, which is generally considered healthy.

What is Rallybio Corporation's debt-to-equity ratio?

Rallybio Corporation (RLYB) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rallybio Corporation's return on assets (ROA)?

Rallybio Corporation (RLYB) had a return on assets of -14.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Rallybio Corporation's P/E ratio?

Rallybio Corporation (RLYB) trades at 2.0x earnings, its market capitalization divided by net income of $45.6M net income, trailing 12 months to June 30, 2026. The market capitalization is $90.3M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Rallybio Corporation's price-to-sales ratio?

Rallybio Corporation (RLYB) trades at 140x sales, its market capitalization divided by revenue of $646K revenue, trailing 12 months to June 30, 2026. The market capitalization is $90.3M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Rallybio Corporation's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Rallybio Corporation (RLYB) held $54.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $29.8M over that year. Dividing the one by the other, the reported balance equals about 22 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Rallybio Corporation's Altman Z-Score?

Rallybio Corporation (RLYB) has an Altman Z-Score of 5.15, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Rallybio Corporation's Piotroski F-Score?

Rallybio Corporation (RLYB) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rallybio Corporation's earnings high quality?

Rallybio Corporation (RLYB) reported a net loss of $9.0M while operations used $29.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.